Cargando…

Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort

Ductal carcinoma in situ (DCIS) is a biologically heterogenous entity with uncertain risk for invasive ductal carcinoma (IDC) development. Standard treatment is surgical resection often followed by radiation. New approaches are needed to reduce overtreatment. This was an observational study that enr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glencer, Alexa C., Miller, Phoebe N., Greenwood, Heather, Maldonado Rodas, Cristian K., Freimanis, Rita, Basu, Amrita, Mukhtar, Rita A., Brabham, Case, Kim, Paul, Hwang, E. Shelley, Rosenbluth, Jennifer M., Hirst, Gillian L., Campbell, Michael J., Borowsky, Alexander D., Esserman, Laura J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10035518/ https://www.ncbi.nlm.nih.gov/pubmed/36970720 http://dx.doi.org/10.1158/2767-9764.CRC-22-0263

Ejemplares similares

Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy
por: Jones, Ella F., et al.
Publicado: (2020)

Modulation of the immune microenvironment of high-risk ductal carcinoma in situ by intralesional pembrolizumab injection
por: Glencer, Alexa C., et al.
Publicado: (2021)

Pathologic and biologic response to preoperative endocrine therapy in patients with ER-positive ductal carcinoma in situ
por: Chen, Yunn-Yi, et al.
Publicado: (2009)

Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
por: Williams, Austin D., et al.
Publicado: (2021)

The breast pre-cancer atlas illustrates the molecular and micro-environmental diversity of ductal carcinoma in situ
por: Nachmanson, Daniela, et al.
Publicado: (2022)

ASO Visual Abstract: Neoadjuvant Endocrine Therapy and Delays in Surgery for Ductal Carcinoma in Situ: Implications for the Coronavirus Pandemic
por: Williams, Austin D., et al.
Publicado: (2021)

The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database
por: Rothschild, Harriet T, et al.
Publicado: (2023)

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study
por: Abel, Mary Kathryn, et al.
Publicado: (2021)

Expansion and conversion of human pancreatic ductal cells into insulin-secreting endocrine cells
por: Lee, Jonghyeob, et al.
Publicado: (2013)

Mammary intraepithelial neoplasia outgrowths (MINO): MINO and human ductal carcinoma in situ
por: Borowsky, AD
Publicado: (2003)

Neoadjuvant Chemotherapy or Endocrine Therapy for Invasive Ductal Carcinoma of the Breast With High Hormone Receptor Positivity and Human Epidermal Growth Factor Receptor 2 Negativity
por: Zhang, Jiaqiang, et al.
Publicado: (2021)

Surgical Management of Axilla Following Neoadjuvant Endocrine Therapy
por: Murphy, Brenna M., et al.
Publicado: (2021)

Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability
por: Scheepens, Josien C.C., et al.
Publicado: (2021)

Mutational profiling of micro-dissected pre-malignant lesions from archived specimens
por: Nachmanson, Daniela, et al.
Publicado: (2020)

Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma
por: Wysocka, Olga, et al.
Publicado: (2016)

An Evaluation of Neoadjuvant Chemoradiotherapy for Patients with Resectable Pancreatic Ductal Adenocarcinoma
por: Jiang, Hui, et al.
Publicado: (2013)

Biochemical Predictors of Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
por: Awad, Seifeldin, et al.
Publicado: (2020)

Is Neoadjuvant Treatment Justified in Clinical T1 Pancreatic Ductal Adenocarcinoma?
por: Kim, Hyung Sun, et al.
Publicado: (2021)

Neoadjuvant chemoradiation alters the immune microenvironment in pancreatic ductal adenocarcinoma
por: Gartrell, Robyn D., et al.
Publicado: (2022)

Endocrine Therapy Initiation among Older Women with Ductal Carcinoma In Situ
por: Anderson, Chelsea, et al.
Publicado: (2017)

Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
por: Mukhtar, Rita A., et al.
Publicado: (2013)

PRoBE the cloud toolkit: finding the best biomarkers of drug response within a breast cancer clinical trial
por: O'Grady, Nicholas, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art
por: Lerebours, Florence, et al.
Publicado: (2021)

The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment
por: Martí, Covadonga, et al.
Publicado: (2021)

Neoadjuvant Endocrine Therapy (NET) in breast cancer – COVID setting
por: Bardoli, Antonio, et al.
Publicado: (2022)

Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy
por: Ferraro, Emanuela, et al.
Publicado: (2020)

Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial
por: Ueno, Takayuki, et al.
Publicado: (2018)

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk
por: Magbanua, Mark Jesus M., et al.
Publicado: (2021)

Association of baseline ROR1 and ROR2 gene expression with clinical outcomes in the I-SPY2 neoadjuvant breast cancer trial
por: Parker, Barbara A., et al.
Publicado: (2023)

Neoadjuvant therapy for pancreatic ductal adenocarcinoma: Opportunities for personalized cancer care
por: Hamad, Ahmad, et al.
Publicado: (2021)

Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma: Where Do We Go?
por: Wang, Chenqi, et al.
Publicado: (2022)

Gene expression profiling of pancreatic ductal adenocarcinomas in response to neoadjuvant chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2023)

Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial
por: Ellis, Matthew J., et al.
Publicado: (2008)

Neoadjuvant endocrine therapy in breast cancer: current role and future perspectives
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2016)

Neoadjuvant Endocrine Therapy in Breast Cancer: Current Knowledge and Future Perspectives
por: Barchiesi, Giacomo, et al.
Publicado: (2020)

Computational drug repositioning for the identification of new agents to sensitize drug-resistant breast tumors across treatments and receptor subtypes
por: Yu, Katharine, et al.
Publicado: (2023)

Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment
por: Ramalingam, Kirithiga, et al.
Publicado: (2023)

Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry
por: Huilgol, Yash S., et al.
Publicado: (2021)

Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index
por: Ragusi, Max A. A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_tonsl7riac3kk0gdu9rsj2em3q